| Genome-wide association study identifies novel breast cancer susceptibility loci DF Easton, KA Pooley, AM Dunning, PDP Pharoah, D Thompson, ... Nature 447 (7148), 1087-1093, 2007 | 2785 | 2007 |
| Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers KB Kuchenbaecker, JL Hopper, DR Barnes, KA Phillips, TM Mooij, ... Jama 317 (23), 2402-2416, 2017 | 2723 | 2017 |
| Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. DW Hedley, ML Friedlander, IW Taylor, CA Rugg, EA Musgrove Journal of Histochemistry & Cytochemistry 31 (11), 1333-1335, 1983 | 2574 | 1983 |
| Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer K Moore, N Colombo, G Scambia, BG Kim, A Oaknin, M Friedlander, ... New England Journal of Medicine 379 (26), 2495-2505, 2018 | 2397 | 2018 |
| Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial A Tutt, M Robson, JE Garber, SM Domchek, MW Audeh, JN Weitzel, ... The Lancet 376 (9737), 235-244, 2010 | 2164 | 2010 |
| Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer J Ledermann, P Harter, C Gourley, M Friedlander, I Vergote, G Rustin, ... New England Journal of Medicine 366 (15), 1382-1392, 2012 | 2098 | 2012 |
| Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation B Kaufman, R Shapira-Frommer, RK Schmutzler, MW Audeh, ... Journal of clinical oncology 33 (3), 244, 2015 | 1901 | 2015 |
| Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised … J Ledermann, P Harter, C Gourley, M Friedlander, I Vergote, G Rustin, ... The lancet oncology 15 (8), 852-861, 2014 | 1716 | 2014 |
| Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial MW Audeh, J Carmichael, RT Penson, M Friedlander, B Powell, ... The lancet 376 (9737), 245-251, 2010 | 1679 | 2010 |
| Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised … E Pujade-Lauraine, JA Ledermann, F Selle, V Gebski, RT Penson, ... The lancet oncology 18 (9), 1274-1284, 2017 | 1663 | 2017 |
| Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial RL Coleman, AM Oza, D Lorusso, C Aghajanian, A Oaknin, A Dean, ... The Lancet 390 (10106), 1949-1961, 2017 | 1594 | 2017 |
| Whole–genome characterization of chemoresistant ovarian cancer AM Patch, EL Christie, D Etemadmoghadam, DW Garsed, J George, ... Nature 521 (7553), 489-494, 2015 | 1490 | 2015 |
| Rethinking ovarian cancer: recommendations for improving outcomes S Vaughan, JI Coward, RC Bast Jr, A Berchuck, JS Berek, JD Brenton, ... Nature Reviews Cancer 11 (10), 719-725, 2011 | 1490 | 2011 |
| BRCA mutation frequency and patterns of treatment response in BRCA mutation–positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group K Alsop, S Fereday, C Meldrum, A DeFazio, C Emmanuel, J George, ... Journal of clinical oncology 30 (21), 2654, 2012 | 1394 | 2012 |
| Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup MA Bookman, MF Brady, WP McGuire, PG Harper, DS Alberts, ... Journal of clinical oncology 27 (9), 1419, 2009 | 855 | 2009 |
| Chemotherapy‐induced peripheral neurotoxicity: a critical analysis SB Park, D Goldstein, AV Krishnan, CSY Lin, ML Friedlander, J Cassidy, ... CA: a cancer journal for clinicians 63 (6), 419-437, 2013 | 792 | 2013 |
| Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer RL Coleman, GF Fleming, MF Brady, EM Swisher, KD Steffensen, ... New England Journal of Medicine 381 (25), 2403-2415, 2019 | 775 | 2019 |
| Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial AM Oza, D Cibula, AO Benzaquen, C Poole, RHJ Mathijssen, GS Sonke, ... The lancet oncology 16 (1), 87-97, 2015 | 632 | 2015 |
| Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG) GJS Rustin, I Vergote, E Eisenhauer, E Pujade-Lauraine, M Quinn, ... International Journal of Gynecologic Cancer 21 (2), 2011 | 619 | 2011 |
| Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin … SB Kaye, J Lubinski, U Matulonis, JE Ang, C Gourley, BY Karlan, ... J Clin Oncol 30 (4), 372-379, 2012 | 589 | 2012 |
